Bulletin
Investor Alert

press release

May 17, 2022, 4:30 p.m. EDT

Regulus Therapeutics to Present at the H.C. Wainwright Global Investment Conference

May 17, 2022 (PRNewswire via COMTEX) -- PR Newswire

SAN DIEGO, May 17, 2022

SAN DIEGO, May 17, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. /zigman2/quotes/202916513/composite RGLS +0.59% , a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that Jay Hagan, President and Chief Executive Officer of Regulus, will present at the H.C. Wainwright Global Investment Conference. An on-demand webcast presentation will be available on Tuesday, May 24, 2022, at 7:00 a.m. ET.

The on-demand webcast will be available under "Events and Presentations" through the investor relations section of the Company's website at www.regulusrx.com and will be archived for 90 days following the presentation date.

About Regulus

Regulus Therapeutics Inc. /zigman2/quotes/202916513/composite RGLS +0.59% is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. Regulus maintains its corporate headquarters in San Diego, CA.

Forward-Looking Statements

Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the Company's employees and their potential impact on our research and development programs. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and in the endeavor of building a business around such drugs, and the risk additional toxicology data may be negative. In addition, while Regulus expects the COVID-19 pandemic to adversely affect its business operations and financial results, the extent of the impact on Regulus' ability to achieve its preclinical and clinical development objectives and the value of and market for its common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the U.S. and in other countries, and the effectiveness of actions taken globally to contain and treat the disease. These and other risks are described in additional detail in Regulus' filings with the Securities and Exchange Commission, including under the "Risk Factors" heading of Regulus most recently quarterly report on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Cision
View original content to download multimedia: https://www.prnewswire.com/news-releases/regulus-therapeutics-to-present-at-the-hc-wainwright-global-investment-conference-301549248.html

SOURCE Regulus Therapeutics Inc.

COMTEX_407349296/2454/2022-05-17T16:30:07

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

Copyright (C) 2022 PR Newswire. All rights reserved

/zigman2/quotes/202916513/composite
US : U.S.: Nasdaq
$ 1.71
+0.01 +0.59%
Volume: 16,821
Nov. 29, 2022 3:58p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$28.63 million
Rev. per Employee
N/A
loading...
/zigman2/quotes/202916513/composite
US : U.S.: Nasdaq
$ 1.71
+0.01 +0.59%
Volume: 16,821
Nov. 29, 2022 3:58p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$28.63 million
Rev. per Employee
N/A
loading...

Comtex

Partner Center

Link to MarketWatch's Slice.